Clinical Trial Search

Primary: Number of Participants With Adverse Events and Serious Adverse Events — 29; 15; 17; 2 Participants

Primary: Shannon Index — 5.02; 4.96; 5.28; 5.73 Shannon index

Primary: Number of Participants With ICU-attributable Staphylococcus Aureus Clinical Cultures — 2708; 3563 participants

Primary: CLR-transformed Abundance of Any Significant Taxa — 3.29; -2.49; -1.59; -2.75 Relative Abundance

Primary: Exposure Adjusted Incidence Rate of AE During Open-label Treatment Epoch Per 100 Subject Years — 101.71 number of AEs per 100 patient-years

Primary: Mean Change in Baseline in Total Corneal Fluoroscein Staining Score — -3.1 score on a scale — p=<0.0001

Primary: Number of Participants With Delay in Follicular Rupture Beyond 5 Days — 46; 43; 12 Participants

Primary: Change From Baseline in IDS-SR-10 Engagement — -8.11 score on a scale — p=<0.0001

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 16; 4; 0; 0 Participants

Primary: Intraocular Pressure — 15.4; 16.3; 16.5; 16.7 millimeters of mercury (mmHg)

Primary: Change in Pain Score at 60 Minutes — 4; 5 score on a scale

Primary: Post-biopsy Pain (VAS-P) — 1; 1 score on a scale

Primary: Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3…

Primary: Numeric Rating Scale (NRS) Pain Scores — 5.0; 1.7 score on a scale

Primary: Percentage of Participants With NPS Improvement From Baseline >=1 at Week 24 — 92.0 percentage of participants